Connect with us

Technology

SingHealth and Philips sign MOU to advance digital-first healthcare to future-proof care delivery

Published

on

New partnership set to accelerate digital healthcare transformation in Singapore, with a focus on co-designing and integrating Artificial Intelligence (AI) and predictive data management to improve patient care by 2028Projects under this partnership aim to:

o  Streamline imaging data workflows by developing a standardized data architecture for better diagnostics and patient outcomes; and
o  Optimize ICU capacity and workflow efficiency by leveraging advanced monitoring and AI tools to help healthcare staff direct care to the right patient at the right time.

SINGAPORE, Feb. 19, 2025 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and SingHealth, Singapore’s largest public healthcare cluster, today announced a strategic partnership to enhance healthcare delivery through deploying innovative technologies and accelerating the digital transformation of the healthcare landscape in Singapore.

This Memorandum of Understanding (MOU) inked between the two organizations signifies a significant step towards building a robust and standardized data architecture for SingHealth. By leveraging Philips state-of-the-art healthcare technologies, the partnership strives to enable seamless digital workflows and improve clinical decision-making. This allows care teams to enhance human interaction with patients, deepen connections and improve outcomes. This will advance SingHealth’s goal to deliver care in a more patient-centric manner through a digital-first strategy.

“We are privileged to partner with SingHealth on this venture to accelerate the digital transformation of healthcare delivery in Singapore,” said Hung Choong Hwang, Country Manager, Philips Singapore. “By combining our technological expertise with SingHealth’s clinical excellence, we aim to set new benchmarks in healthcare innovation, quality and resilience, in line with our vision of delivering better care for more people.”

Under the terms of the MOU, Philips and SingHealth will set up dedicated teams to drive three key projects over the course of three years, focused on integrating imaging data with AI, predictive data management to enable actionable insights and optimizing ICU capacities by boosting monitoring and patient assessment capabilities. As projects under the MOU progress, its potential scope may widen beyond these initial three projects to include other additional areas of collaboration where synergies and opportunities are identified by both parties.

Enhancing healthcare delivery with a digital-first approach through three key projects

1.  Getting the right information seamlessly to the right expert: Integrated imaging with AI embedded into workflows

This project will automate and streamline Enterprise Digital Image workflows, including acquisition, storage, distribution, retrieval and archival processes. By centralizing and modernizing the architecture for Radiology, Pathology, and other images for clinical practice, the project aims to standardize clinical access and enhance electronic medical records connectivity. Starting with Radiology, the project will also explore innovations such as the use of embedded AI to automate and integrate workflows.

2.  Supporting staff with clinical decision-making: Next-generation predictive enterprise data management

Next-generation data analytics will be deployed to provide real-time, actionable insights to sharpen clinical decision-making. With fully-integrated live stream clinical data as a foundation, the goal is to implement advanced device interface models and introduce programmable AI and visualization layers to support clinical care and enterprise storage. This capability, implemented at scale across the cluster, will be a springboard enabling SingHealth to develop more pioneering innovations in this space globally.

3.  Enhancing patient care with Smart ICU: Optimizing capacity based on patient acuity

New clinical decision support tools and advanced monitoring equipment will be used to optimize ICU capacity and enhance efficiency and care quality.

A unified monitoring system, aligned with clinical workflows such as alarm assessments, will be established. The infrastructure will be co-designed to achieve interoperability, ensure cloud and cybersecurity alignment, and support clinical workflow assessments. Additionally, AI-powered models and algorithms will be jointly developed to monitor developments in patients’ conditions, optimize alarm management, and deliver clinical parameter dashboards and avatars.

Partnerships key to future-proofing healthcare delivery with innovation

One of the key challenges in the complexities of the healthcare system is the ability to access and integrate different data sources to form a cohesive patient story. Accurate and timely access to data at critical points in a patient’s journey is key in the digital transformation of the healthcare system. According to the Singapore FHI 2024 report findings, more than one-third (37%) of healthcare leaders surveyed are looking to external partnerships to use data analytics for more informed decision-making.

Please refer to Annex for more info on Singapore findings of the Philips Future Health Index (FHI) 2024 report.

Philips has previously partnered SingHealth in the implementation of an iECG initiative to transform the delivery of cardiovascular care in Singapore. Philips also partnered Singapore General Hospital to advance its medical imaging capabilities.

“We believe in harnessing the power of strategic partnerships to address the unique healthcare needs of the Asia Pacific. By conducting thorough reviews of current capacities, processes and workflows, and thoughtfully integrating advanced technologies in a way that best supports staff, we are dedicated to improving healthcare outcomes and efficiency across this diverse and dynamic region,” said Jasper Westerink, Acting Managing Director, Philips APAC. “I’m excited about how our upcoming projects will positively impact patient care and digital healthcare innovation in the region, especially since SingHealth is Singapore’s largest healthcare group and has a track record of setting standards of excellence in patient-centred clinical care, and since Singapore is a key medical hub.”

Mr Lawrence Loke, Group Chief Information Officer, SingHealth, said, “This collaboration between SingHealth and Philips is a big stride forward in accelerating healthcare innovation in Singapore. By combining our deep and broad range of clinical expertise with Philips’ cutting-edge technology, we are prioritizing the needs of our patients in reimagining healthcare delivery. From ‘Smart ICUs’ to AI-driven diagnostics, our singular goal is to enhance patient outcomes and experiences. In our efforts to pilot transformative care models, we hope that our patients will receive personalized, timely and accessible care that is focused on achieving the best outcomes possible for them.”

As a key medical hub in the Asia Pacific, partnerships like these position Singapore well in leading the charge to pioneer and deploy next-generation healthcare technologies, driving efficiency, better care, and more accessible health services for more people across the region.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Annex

Addressing healthcare system challenges: Workforce, data and workflow optimization

With Singapore’s population set to become “super-aged” by 2026, and 21% of its population over the age of 65, the healthcare system faces mounting pressures.[1] According to the Singapore findings of the Philips Future Health Index (FHI) 2024 report, nearly two-thirds (65%) of healthcare leaders report that workforce shortages are leading to staff having less time with patients, higher patient-to-staff ratios and/or an increase in clinical errors. These challenges highlight the urgent need to augment clinical manpower and address growing patient workloads and demands on Singapore’s health services.

In addition to workforce shortages, healthcare leaders identified workflow prioritization as a key area for automation, which can help healthcare professionals better manage high patient volumes without compromising on care quality. For instance, automated initial screening of medical images can help prioritize cases and direct them to the right sub-specialty radiologist. Similarly, automated triaging systems can assist emergency department staff, improving efficiency and reducing strain on personnel.

Philips FHI 2024 report also revealed that 84% of Singapore’s healthcare leaders face data integration challenges, which hamper their ability to deliver timely, high-quality care. The inability to fully utilize data has wide-ranging effects, from financial and operational concerns to limiting coordination between clinicians and reducing their time spent with patients. Overcoming barriers to integrate data accessibly across clinical operations, human resources, and financials for reporting is therefore critical for continuous improvement, better decision-making and better patient empowerment.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/singhealth-and-philips-sign-mou-to-advance-digital-first-healthcare-to-future-proof-care-delivery-302379667.html

SOURCE Royal Philips

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

ASUS Accelerates Enterprise AI at Scale with 6th-Gen AMD EPYC Server CPUs

Published

on

By

 ASUS leverages 6th-gen AMD EPYC Server CPUs to deliver scalable, efficient compute for enterprise AI, cloud, virtualization and business-critical workloads

SAN FRANCISCO, July 24, 2026 /PRNewswire/ — ASUS today announced its groundbreaking new server lineup powered by the AMD EPYC™ 9006 processors, engineered to deliver unmatched performance for the most demanding intensive enterprise workloads. This advanced portfolio introduces two highly optimized series with efficiency-optimized AMD EPYC SP8 server CPU, the flagship dual-socket ASUS RS700A/720A for extreme compute density and the single-socket ASUS RS500A/520A for superior space efficiency and deployment flexibility.

Both series integrate full PCIe® 6.0, leading memory support, and high-density E3.S storage, all underpinned by proprietary ASUS innovations for superior thermal management and operational efficiency to meet and exceed the rigorous demands of enterprise AI, virtualization, storage and cloud environments.

“The new ASUS server series, powered by 6th-gen AMD EPYC server CPUs, is engineered to power every enterprise workload with flexible, scalable infrastructure,” Paul Ju, Senior Vice President of ASUS, commented, “This launch marks a significant milestone for ASUS and our clients. The new series empowers businesses with a resilient foundation to achieve unprecedented computing efficiency and accelerating AI innovation with inference.”

ASUS expands 6th-gen AMD EPYC server portfolio with dual optimized series

ASUS has introduced a new server lineup segmented into two distinct series, each precisely engineered to meet diverse enterprise demands.

The flagship RS700A/720A series (dual-socket) delivers extreme compute density, making it ideal for AI inferencing, and complex simulations. It offers exceptional bandwidth with PCIe 6.0, memory leadership via 32 DIMM slots supporting ultrafast MRDIMM, and high-density storage with up to 32 E3.S bays in a compact 2U form factor.

Complementing this is the RS500A/520A series (single-socket), a highly efficient and space-optimized solution with depth under 800mm, perfect for mainstream enterprise workloads and rack-constrained environments. Featuring full PCIe 6.0 capabilities, E3.S storage support, and modular scalability through shared components with the RS700A and RS720A series, it provides uncompromised performance in a streamlined, deployment-friendly design.

ASUS elevates the AMD EPYC platform with cutting-edge proprietary innovations

ASUS has significantly advanced the AMD EPYC 9006 platform with a series of proprietary engineering breakthroughs focused on superior reliability, thermal management, and operational efficiency.

The DC-MHS modular architecture features a zone-partitioned chassis that separates I/O, HPM, fan, and storage modules to accelerate development, reduce capital costs, and enable rapid serviceability. The patented ASUS DIMM.2 Innovation repositions M.2 storage to the cooler DIMM region, eliminating thermal throttling without extra heatsinks and unlocking greater scalability. Thermal Radar 3.0 with PID Control delivers precise real-time fan regulation via advanced algorithms, reducing energy use and maintaining peak performance under heavy enterprise-level workload.

Completing the suite is the optimized tool-less operational-velocity design, which boosts maintenance efficiency, maximizing uptime and lowering TCO and sustaining peak performance even under volatile, high-load AI/HPC workloads.

AVAILABILITY & PRICING

ASUS RS700A/720A series and RS500A/520A series servers will be available soon. Please contact your local ASUS representative for further information.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/asus-accelerates-enterprise-ai-at-scale-with-6th-gen-amd-epyc-server-cpus-302833931.html

Continue Reading

Technology

Fractal posts 20% revenue growth and 92% net income growth in Q1 FY27

Published

on

By

Adjusted EBITDA Grows at 35% YoYGross Margin up 29 bps1 to 46%; Adjusted EBITDA Margin up 189 bps to 17%

NEW YORK, July 24, 2026 /PRNewswire/ — Fractal Analytics Ltd (BSE: 544700) (NSE: FRACTAL) announced its consolidated financial results for Q1 FY27, ending June 30, 2026.

In Q1 FY27, the Company reported consolidated operating revenue of INR 9,125 m, a growth of 20% year on year (YoY). Revenue growth was led by the company’s Healthcare and Life Sciences (HLS) industry, which clocked 69% growth YoY. Strong sustained growth in HLS over the last several quarters has resulted in it becoming the second largest industry in the portfolio. Banking, Financial Services and Insurance (BFSI) also performed very well, growing 36% YoY in Q1. Fractal’s largest industry, Consumer Packaged Goods and Retail (CPGR), continued to gather momentum, growing 19% YoY. On the other hand, TMT declined 22% YoY.

Fractal’s focus on deepening customer relationships continues to yield good outcomes. Its clients collectively increased their spending with the company, as reflected in the Net Revenue Retention2 of 117% in Q1. Further, its Net Promoter Score (NPS) during the period stood at 77.

The company reported improved profit margins at all levels. Gross Margin in Q1 was at 46%, while Adjusted EBITDA Margin expanded by 189 bps YoY to 17%. Net Income grew 92% YoY to INR 723 m.

Commenting on the performance, Srikanth Velamakanni, Group CEO and Executive Vice-Chairman, said:

“Enterprises are putting real transformation budgets behind AI now and we’re seeing it directly in the size of the deals coming to us. TMT was the drag on our headline growth this quarter. Excluding TMT, our business grew 35% year on year, which is a better read on the underlying demand we’re seeing.

As data sovereignty becomes a bigger priority for governments and enterprises, and as open-weight models keep improving, clients need a partner who can work across models and infrastructure. We have invested heavily in our people, our research, and our own intellectual property to be that partner.”

1 Basis points = 1/100th of 1%
2 Net Revenue Retention in our Fractal.ai segment measures how effectively we retain and expand revenue from our existing clients over a defined period and is calculated by comparing the current period’s revenue from the clients who existed at the start of the period, with their revenue in the previous period – including the effects of upsells, cross-sells and contractions

About Fractal 

Fractal Analytics Ltd (BSE: 544700) (NSE: FRACTAL) is a globally recognized pure-play enterprise AI company trusted by Fortune 500®-sized enterprises to power decision-making through AI services, solutions, and products, anchored by Cogentiq, its flagship agentic AI platform. With over 6,000 professionals across North America, EMEA, and Asia-Pacific, Fractal partners with business leaders to drive competitive differentiation for their organizations by embedding AI into critical decisions across business functions and industry verticals.

Fractal invests more than 6% of its revenue in AI R&D, supporting foundational AI research, product development, and IP creation that address both immediate client needs and long-term technological advancement. Fractal’s track record includes developing proprietary models and products such as Cogentiq Health – Vaidya.ai and Cogentiq Data Science – PiEvolve, as well as incubating and spinning out Qure.ai, a global healthcare AI leader focused on the rapid identification and management of tuberculosis, lung cancer, and stroke (or critical health conditions). Fractal’s suite of businesses consists of Asper.ai (a Revenue Growth Management product for CPG companies) and Analytics Vidhya (an Ed-tech platform).

For more information, go to www.fractal.ai.

Logo: https://mma.prnewswire.com/media/2931510/5858548/Fractal_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/fractal-posts-20-revenue-growth-and-92-net-income-growth-in-q1-fy27-302833932.html

SOURCE Fractal Analytics Limited

Continue Reading

Technology

Xryma Plc : Pre-Listing Liquidity Facility and Price Discovery Process

Published

on

By

NICOSIA, Cyprus, July 24, 2026 /PRNewswire/ — Xryma Plc (“Xryma”)  announces its intention to reapply within the next twelve months for admission to list on Euronext Paris (“Euronext”), with such admission being subject to Euronext’s approval. Before submitting its application, Xryma intends to launch a pre-listing liquidity facility and price discovery process, comprising a private placement to institutional and qualified investors alongside a secondary market offer to Xryma existing shareholders (“shareholders”) wishing to exit prior to listing.  

The admission referred to above that is subject to the approval of Euronext may also be subject to approval by relevant regulatory authorities, and no assurance can be given that approval will be granted or as to the timing of any admission.

The pre-listing liquidity facility and price discovery process is designed to:

Enable shareholders seeking an exit to participate without the need to open an EU brokerage account,Provide a clear and orderly opportunity for existing shareholders to sell all or part of their holdings ahead of any potential admission to trading on Euronext Paris,Enable shareholders to sell all or part of their holdings at the same price at which qualified and institutional investors subscribe for shares in the Company,Establish, through a bookbuild with qualified and institutional investors, a market-validated referenced price for Xryma shares ahead of any potential admission on Euronext Paris (the “Primary Market Placement Price”),Support orderly trading upon potential admission.

Individual shareholder mailouts explaining the details of the pre-listing liquidity facility scheme with instructions and necessary documentation will be conducted during August 2026.

As the Primary Market Placement Price is to be determined by the subsequent bookbuild, shareholders will be given the opportunity to set a floor price which will result in the sale of their shares if the Primary Market Placement Price is higher.  Shareholders will receive the Primary Market Placement Price minus applicable fees.

Shareholders and Investors may be scaled back to match corresponding demand from the other party, with partial fulfilment a possibility if the Company cannot match supply to demand.

Completion of the process is subject to achieving a level of institutional and qualified investor demand that the Board considers appropriate to support an orderly market should Xryma subsequently be admitted to trading on Euronext Paris.

Participation is entirely voluntary. Shareholders who do not wish to sell will simply retain their shares. Shareholders that do not intend to participate should continue to onboard with a Euronext participating broker, or a Euroclear ESES custodian, per previous communications.

The major shareholders, SCP Select All Enterprise (Monaco) and SCP Red 5 Solutions (Monaco) will not participate in the offer and will be subject to lock up arrangements.

Mr Nikogiannis (John) Karantzis, CEO of Xryma Plc comments: “Our shareholders have told us they would value a straightforward way to realise their holdings without the time and cost of opening an EU brokerage account. This process is our response to that feedback. We are structuring the placement to be large enough to establish a credible reference price whilst limiting dilution, with demand directed first towards meeting shareholder sell interest. We look forward to updating the market on the revised timetable in due course.”

Shareholders seeking a more detailed explanation of the pre-listing liquidity facility and price discovery process, should refer to the guide available at https://www.xryma.com/investors

Important Information & Disclaimers

This press release may contain inside information within the meaning of Article 7(1) of Regulation (EU) 596/2014 (Market Abuse Regulation).

This publication is not for publication or distribution or release, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Canada, Australia, South Africa, Japan or any other jurisdiction where such an announcement would be unlawful. The distribution of this publication may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. No action has been taken that would permit an offering of the treasury shares or possession or distribution of this publication in any jurisdiction where action for that purpose is required.

This publication does not constitute or form part of an offer for sale or solicitation of an offer to purchase or subscribe for securities in the United States, Canada, Australia, South Africa, Japan or any other jurisdiction and the securities referred to herein have not been registered under the securities laws of any such jurisdiction. Any New Shares (if such are issued) will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any State or any other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of, the Securities Act and in compliance with all applicable securities laws of any State or any other jurisdiction of the United States. No public offering of securities is being made in the United States or in any other jurisdiction.

The information set forth herein must not be distributed in any jurisdiction where such distribution is unlawful, and any recipients are requested to inform themselves about and to observe such restrictions.

The Offering referred to herein by Xryma Plc will only be made in accordance with all applicable corporate and securities laws. Any shares referred to herein will exclusively be offered or sold in reliance on any applicable exemptions from prospectus or registration requirements in any jurisdiction. In member states of the European Economic Area, this publication is only addressed to and directed at persons who are ‘qualified investors’ within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (as amended and including any relevant delegated regulations, the “Prospectus Regulation”) or in any other circumstances falling within exemptions available in the relevant member state under Article 1(4) and/or 1(5) of the Prospectus Regulation. In the United Kingdom, this publication is only addressed to and directed at qualified investors within the meaning of the Prospectus Regulation, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (“EUWA”), who are persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order”), (ii) falling within article 49(2)(a) to (d) (high net worth companies, incorporated associations, etc.) of the Order, or (iii) to whom it may otherwise be lawfully communicated; any other persons in the United Kingdom should not take any action on the basis of this publication and should not act on or rely on it.

This publication does not constitute a recommendation concerning the prospective Offering. This announcement does not constitute an Offer or invitation to subscribe.

This announcement includes statements that are, or may be deemed to be, ‘forward looking statements’. These forward-looking statements can be identified by the use of forward looking terminology, including the terms ‘believes’, ‘estimates’, ‘anticipates’, ‘expects’, ‘intends’, ‘may’, ‘will’, or ‘should’ or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances which may or may not occur. Many of these factors are beyond the control of the Company. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results and circumstances may vary materially from those described in this announcement as anticipated, believed, estimated or expected.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/xryma-plc–pre-listing-liquidity-facility-and-price-discovery-process-302833658.html

Continue Reading

Trending